Current challenges in HER2-positive breast cancer

Fabio Puglisi, Caterina Fontanella, Vito Amoroso, Giulia Valeria Bianchi, Giancarlo Bisagni, Cristina Falci, Andrea Fontana, Daniele Generali, Lorenzo Gianni, Antonio Grassadonia, Luca Moscetti, Ilaria Portarena, Emanuela Rossi, Paolo Marchetti

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve.This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.

Original languageEnglish
Pages (from-to)211-221
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume98
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Breast Neoplasms
Therapeutics
Heart Diseases
Safety
Neoplasms
Trastuzumab
pertuzumab
ado-trastuzumab emtansine

Keywords

  • Breast cancer
  • Dual targeting
  • HER2
  • Lapatinib
  • Neoadjuvant
  • Pertuzumab
  • Trastuzumab
  • Trastuzumab-emtansine

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Current challenges in HER2-positive breast cancer. / Puglisi, Fabio; Fontanella, Caterina; Amoroso, Vito; Bianchi, Giulia Valeria; Bisagni, Giancarlo; Falci, Cristina; Fontana, Andrea; Generali, Daniele; Gianni, Lorenzo; Grassadonia, Antonio; Moscetti, Luca; Portarena, Ilaria; Rossi, Emanuela; Marchetti, Paolo.

In: Critical Reviews in Oncology/Hematology, Vol. 98, 01.02.2016, p. 211-221.

Research output: Contribution to journalArticle

Puglisi, F, Fontanella, C, Amoroso, V, Bianchi, GV, Bisagni, G, Falci, C, Fontana, A, Generali, D, Gianni, L, Grassadonia, A, Moscetti, L, Portarena, I, Rossi, E & Marchetti, P 2016, 'Current challenges in HER2-positive breast cancer', Critical Reviews in Oncology/Hematology, vol. 98, pp. 211-221. https://doi.org/10.1016/j.critrevonc.2015.10.016
Puglisi, Fabio ; Fontanella, Caterina ; Amoroso, Vito ; Bianchi, Giulia Valeria ; Bisagni, Giancarlo ; Falci, Cristina ; Fontana, Andrea ; Generali, Daniele ; Gianni, Lorenzo ; Grassadonia, Antonio ; Moscetti, Luca ; Portarena, Ilaria ; Rossi, Emanuela ; Marchetti, Paolo. / Current challenges in HER2-positive breast cancer. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 98. pp. 211-221.
@article{05cac06361344257af0ec4f3ac33ae17,
title = "Current challenges in HER2-positive breast cancer",
abstract = "The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve.This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.",
keywords = "Breast cancer, Dual targeting, HER2, Lapatinib, Neoadjuvant, Pertuzumab, Trastuzumab, Trastuzumab-emtansine",
author = "Fabio Puglisi and Caterina Fontanella and Vito Amoroso and Bianchi, {Giulia Valeria} and Giancarlo Bisagni and Cristina Falci and Andrea Fontana and Daniele Generali and Lorenzo Gianni and Antonio Grassadonia and Luca Moscetti and Ilaria Portarena and Emanuela Rossi and Paolo Marchetti",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.critrevonc.2015.10.016",
language = "English",
volume = "98",
pages = "211--221",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Current challenges in HER2-positive breast cancer

AU - Puglisi, Fabio

AU - Fontanella, Caterina

AU - Amoroso, Vito

AU - Bianchi, Giulia Valeria

AU - Bisagni, Giancarlo

AU - Falci, Cristina

AU - Fontana, Andrea

AU - Generali, Daniele

AU - Gianni, Lorenzo

AU - Grassadonia, Antonio

AU - Moscetti, Luca

AU - Portarena, Ilaria

AU - Rossi, Emanuela

AU - Marchetti, Paolo

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve.This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.

AB - The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve.This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.

KW - Breast cancer

KW - Dual targeting

KW - HER2

KW - Lapatinib

KW - Neoadjuvant

KW - Pertuzumab

KW - Trastuzumab

KW - Trastuzumab-emtansine

UR - http://www.scopus.com/inward/record.url?scp=84957668960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957668960&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.10.016

DO - 10.1016/j.critrevonc.2015.10.016

M3 - Article

AN - SCOPUS:84957668960

VL - 98

SP - 211

EP - 221

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -